Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety of Roflumilast in COPD
NCT00246935Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- May 2005
- Primary completion
- Jan 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of roflumilast in chronic obstructive pulmonary disease (COPD), sponsored by AstraZeneca. Started May 2005; status: completed.
02
Drugs
roflumilast
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT00246935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00246935.